Mark Kidd

Laboratory and Scientific Director at Wren Laboratories
Mark Kidd, PhD, DABCC has worked and published extensively in the area of Neuroendocrine Tumor (NET) disease, and is the Scientific Director of Wren Laboratories.
NETest

Clinical Utility of Multigene Blood Analysis

NETest is 4X more precise than CgA and 10X more precise for monitoring disease progress.

Read Article
About Wren

Senator Murphy names Wren Connecticut Innovator of the Month

Company lauded for quick development of saliva-based Covid-19 Test.

Read Article
About Wren

Branford Lab offers saliva-based Covid-19 Test

Wren Laboratories receives FDA emergency use authorization for pain-free Covid-19 PCR test.

Read Article
About Wren

The future of long-term COVID-19 testing is now

Wren’s Mark Kidd: Easier, more accurate Covid-19 testing enables society to “get back to normal”.

Read Article
About Wren

Branford-invented Covid-19 Saliva Test Available

Middletown, CT is the latest community test center to adopt the painless, accurate saliva test.

Read Article
Covid-19 Test

Saliva tests at Community Covid-19 Test Sites

Connecticut community test sites are adopting the Wren Labs saliva-based Covid-19 test.

Read Article
Covid-19 Test

Wren Covid-19 Test receives FDA EUA for ages 5+

Saliva-based Covid-19 PCR test has been FDA approved for use in children ages five and over.

Read Article
Covid-19 Test

Covid-19 Saliva Test superior to nasal swab

Saliva-based Covid-19 tests are quicker and safer than nasal swab tests, study finds.

Read Article
NETest

NETest shows blood viable for tumor monitoring

Wren Lab’s liquid biopsy has proven an effective biomarker for cancer treatment decision-making.

Read Article
NETest

Blood test predicts NET cancer therapy success

Noninvasive NETest-type diagnostics predict therapy success and provide therapy monitoring.

Read Article
NETest

NETest possible predictor of tumor recurrence

NETest is a highly accurate post-operative predictor of neuroendocrine tumor recurrence.

Read Article